Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19

Pfizer and the Medicines Patent Pool (MPP) have reached a voluntary licensing agreement for Paxlovid (nirmatrelvir+ritonavir), a novel antiviral for coronavirus disease 2019 (COVID-19) taken orally in the first 5 days from symptom onset. The Pfizer-MPP deal enables 95 low- and middle-income countrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Pepperrell, Toby, Ellis, Leah, Wang, Junzheng, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383702/
https://www.ncbi.nlm.nih.gov/pubmed/36176569
http://dx.doi.org/10.1093/ofid/ofac174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383702/
https://www.ncbi.nlm.nih.gov/pubmed/36176569
http://dx.doi.org/10.1093/ofid/ofac174

Ejemplares similares